Precigen, Inc. (PGEN) Stock Price & Analysis
Precigen, Inc. (PGEN) rose 3.92% to USD 3.71 as of June 9, 2026 at 23:55 UTC, according to Nexqual real-time market data.
PGEN last closed at USD 3.57; the session ranged USD 3.56–3.75 on volume of 3,474,037 shares. Market capitalization is $1.32B, with a 52-week range of USD 1.38–5.47 (NMS). Source: Nexqual, June 9, 2026 at 23:55 UTC.
Key Statistics (as of June 9, 2026 at 23:55 UTC)
| Price | USD 3.71 |
|---|---|
| Change | ▲ 3.92% (up) |
| Previous Close | USD 3.57 |
| Open | USD 3.66 |
| Day Range | USD 3.56 – 3.75 |
| 52-Week Range | USD 1.38 – 5.47 |
| Volume | 3,474,037 shares |
| Market Cap | $1.32B |
| Exchange | NMS |
Technical Analysis (PGEN)
Nexqual's technical model rates PGEN "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:55 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.99 (neutral) |
| vs SMA50 | Below (USD 4.08) |
| MACD | -0.11 (negative) |
Analyst Ratings (PGEN)
Wall Street analysts rate PGEN "Buy" based on 2 analysts, with a mean price target of USD 12.45 (range USD 11–13.9), per Nexqual as of June 9, 2026 at 23:55 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 12.45 |
| High Target | USD 13.9 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (PGEN)
| Next Earnings Date | 2026-08-11 |
|---|---|
| Revenue Estimate | $27.84M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.02 vs est -0.04 ▲ beat |
| 2025-12-31 | USD -0.01 vs est -0.08 ▲ beat |
| 2025-09-30 | USD -1.06 vs est -0.1 ▼ miss |
| 2025-06-30 | USD -0.08 vs est -0.08 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Financials & Fundamentals (PGEN)
| Total Revenue | $31.59M |
|---|---|
| Revenue Growth (YoY) | +1633.90% |
| Gross Margin | -35.38% |
| Operating Margin | -25.78% |
| Profit Margin | +0.00% |
| ROE | -1145.42% |
| Debt / Equity | 485.55 |
| Current Ratio | 4.82 |
| Total Cash | $56.25M |
| Total Debt | $98.25M |
| Free Cash Flow | $-90.11M |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Financial Health Score (PGEN)
Nexqual rates Precigen, Inc.'s overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:55 UTC.
| Growth | Strong — Revenue +147% YoY (annual) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $56M cash vs $98M debt |
| Cash Flow | Weak — FCF negative: -$90M, burning cash |
| Efficiency | Critical — ROE -1145%, ROA -42.1% |
Ownership (PGEN)
| Insider Ownership | +13.71% |
|---|---|
| Institutional Ownership | +71.09% |
| Shares Outstanding | 356.51M |
| Float | 189.46M |
| Short % of Float | +20.59% |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Leadership (PGEN)
Precigen, Inc. is led by Helen Sabzevari MPH (age 63), President, CEO & Director, per Nexqual as of June 9, 2026 at 23:55 UTC.
| President, CEO & Director | Helen Sabzevari MPH (age 63) |
|---|---|
| Executive Chairman | Randal J. Kirk (age 72) |
| Chief Financial Officer | Harry Thomasian (age 63) |
| Chief Operating Officer | Rutul R. Shah (age 44) |
Major Backers & Investors (PGEN)
Notable institutional backers of Precigen, Inc. include Patient Capital Management, LLC, Advisor Managed Portfolios-Patient Opportunity Trust, Diametric Capital, Lp, according to Nexqual as of June 9, 2026 at 23:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Patient Capital Management, LLC | 5% |
| Advisor Managed Portfolios-Patient Opportunity Trust | 3.62% |
| Diametric Capital, Lp | 1.91% |
| Point72 Asset Management, L.P. | 1.86% |
| Tang Capital Management, LLC | 1.8% |
| Occam Crest Management LP | 1.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.17% |
| State Street | 4.93% |
| Vanguard Group | 3.96% |
| Geode Capital | 1.29% |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
From Precigen, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
- The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
- It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors.
- In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| TSHA | Taysha Gene Therapies, Inc. | USD 5.36 | ▼ 2.55% |
| PHGE | BiomX Inc. | USD 0.68 | ▼ 5.35% |
| GOSS | Gossamer Bio, Inc. | USD 0.16 | ▼ 8.57% |
| REPL | Replimune Group, Inc. | USD 9.24 | ▼ 2.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:55 UTC. This page is informational and not investment advice.